

In re Generic Pharmaceuticals Pricing Antitrust Litigation
Settlement Administrator
PO Box 2750
Portland, OR 97208-2750

Court-Approved Legal Notice

*In re Generic Pharmaceuticals Pricing
Antitrust Litigation,*

Case No. 16-md-2724
United States District Court for the Eastern
District of Pennsylvania

**If you are a dispenser of drugs in
the U.S. that purchased one or more
“Drugs at Issue” from January 1, 2010,
through March 5, 2024, a class action
settlement may affect your rights.**

A Court has authorized this notice.

This is **not** a solicitation from a lawyer.

www.GenericPharmaceuticalsAntitrust.com

1-877-644-0182

A \$5.5 million Settlement has been reached in a class action antitrust lawsuit between Indirect Reseller Plaintiffs and Defendant Apotex Corp. (“Apotex”). The Settlement only applies to Apotex, with the lawsuit continuing against other Defendants. The lawsuit is called *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Case No. 16-md-2724 (E.D. Penn.). The Settlement will resolve claims that Apotex participated in one or more unlawful conspiracies to raise, fix, maintain, and/or stabilize prices, rig bids, and allocate markets and customers for “Drugs at Issue” in violation of Section 1 of the Sherman Act and various state antitrust, unfair competition, unjust enrichment, and consumer protection laws. The “Drugs at Issue” are listed at www.GenericPharmaceuticalsAntitrust.com.

Who is Included? Records show you are a member of the Settlement Class defined as: All dispensers of drugs (including Clinics, Hospitals and Independent Pharmacies) in the United States and its territories that purchased one or more Drugs at Issue from January 1, 2010 through March 5, 2024, including (a) those that purchased directly from distributor AmerisourceBergen Drug Corporation, Cardinal Health, Inc., Red Oak Sourcing, LLC, The Harvard Drug Group, LLC, HD Smith LLC, McKesson Corporation, Morris & Dickson Co., LLC or Walgreens Boot Alliance, Inc. or their subsidiaries; and (b) those that purchased indirectly from any Defendant in the MDL.

What does the Settlement Provide? If the Settlement is approved, Apotex is required to pay \$5,537,000 to resolve all Settlement Class Members’ legal claims against Apotex for the Released Claims (as defined in the Settlement Agreement). Apotex has also agreed to provide specified cooperation in the Indirect Reseller Plaintiffs’ continued prosecution of the lawsuit. There will be no payments to the Settlement Class at this time. You will be notified later of an opportunity to file a Claim Form.

Other Options. If you do not want to be legally bound by the Settlement, you must opt out of the Settlement **no later than January 16, 2025**. If you do not opt out, you will give up the right to sue and will release the Defendant and Released Parties about the legal claims in this Action. If you do not opt out, you may object to the Settlement by **January 16, 2025**. The Long Form Notice on the Settlement Website has instructions on how to opt out or object. If you do nothing, you will remain in the Settlement Class and you may participate in any monetary distribution later, and you will be bound by the Settlement and any judgements and orders. The Court will hold a Final Approval Hearing on **March 17, 2025**, to consider whether to approve the Settlement, Class Counsel’s attorneys’ fees request of up to \$500,000 of the \$5.5 million Settlement Fund, as well as any objections to the Settlement. You or your personal attorney may attend and ask to appear at the hearing, but you are not required to do so. The hearing may be held remotely, and if so, instructions will be at www.GenericPharmaceuticalsAntitrust.com.

This notice is a summary. Learn more about the Settlement at www.GenericPharmaceuticalsAntitrust.com, or by calling toll free 1-877-644-0182.